Patritumab deruxtecan, CAS 2227102-46-5

Product Description: Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity[1].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Koyama K, et al. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression. PLoS One. 2022 May 3;17(5):e0267027.

CAS Number: 2227102-46-5

Molecular Weight: 158000 (average)

Compound Purity: 99.08

Research Area: Cancer

Solubility: H2O

Target: Antibody-Drug Conjugates (ADCs)

• Artikelnummer: MEXHY-P99813-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99813-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK